HDAC

“Opportunities and Challenges” in the development of the HDACs drugs for cancers

“Opportunities and Challenges” in the development of the HDACs drugs for cancers

Despite the popularity in the development of histone deacelytase (HDAC) inhibitors, the indications of the five already approved HDAC inhibitor drugs on the market are limited to peripheral T-cell lymphoma […]